toreforant
Small moleculeexperimental
Clinical trial activity
10 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2010 (NCT00941707)
Timeline
Indications
Mechanism of action
- Histamine H4 receptorANTAGONIST
HRH4 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(C)c2nc(-c3cnc(NCCCC4CCN(C)CC4)nc3C)[nH]c2c1- Mol. weight
- 392.55 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3301609 ↗
- ChEMBLCHEMBL3301614 ↗
Also known as
- jnj 38518168
- jnj 38518168
- jnj-38518168
- jnj-38518168
- jnj-38518168
- toreforant
- toreforant
- toreforant
- toreforant tartrate
- toreforant tartrate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02295865 | Phase 2 | Nov 1, 2014 | Johnson and Johnson |
| NCT01823016 | Phase 2 | Sep 1, 2013 | Johnson and Johnson |
| NCT01862224 | Phase 2 | Jul 1, 2013 | Johnson and Johnson |
| NCT01863784 | Phase 1 | Apr 1, 2013 | Johnson and Johnson |
| NCT01679951 | Phase 2 | Oct 1, 2012 | Johnson and Johnson |
| NCT01690286 | Phase 1 | Oct 1, 2012 | Johnson and Johnson |
| NCT01970020 | Phase 1 | Oct 1, 2012 | Johnson and Johnson |
| NCT01442532 | Phase 1 | Sep 1, 2011 | Johnson and Johnson |
| NCT01450982 | Phase 1 | Jun 1, 2011 | Johnson and Johnson |
| NCT00941707 | Phase 2 | Feb 1, 2010 | Johnson and Johnson |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 10 | 10 | 2 | 2010 |
1 organizations
Page 1 / 1